Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients at least 19 years of age~2. Patients diagnosed with degenerative arthritis~3. Patients with IKDC(Knee Documentation Committee subjective score) score of 60 or below~4. Patients with 100 mm VAS(Visual Analog Scale) score of 40 or above~5. With Grade 3 osteoarthritis as determined by the radiographic criteria of Kellgren and Lawrence~6. With an International Cartilage Repair Society(ICRS) Grade III or IV cartilage damage in the major lesions, as confirmed through an MRI scan~7. With a Body Mass Index(BMI) of higher than18.5 and lower than 30~8. Patients who satisfies the clinical/radiational criteria by the American College of Rheumatology (ACR) guidelines, and applies to one of the following.~   * Older than 50~  * Morning stiffness for less than 30 minutes~  * Crepitus and Osteophytes~9. With major lesions concentrated in one section of the knee, and with the major lesions considered the main cause of the clinical symptoms~10. With no alleviation of the symptoms even after at least three months of non-surgical treatment~11. Healthy, with no major findings from the physical examination, hematology, serum chemistry, and urine tests, and no significant medical history~12. Agreed to use an effective contraceptive method during the study period~13. Voluntarily agreed to participate in this study, and signed the informed consent form~Exclusion Criteria:~1. Showed clinically significant hematology, serum chemistry, and urine test results at the screening visit~2. Regarding inclusion criteria 6. following patients should not be included~   * patients with a major lesion of ICRS grade 4 which is larger than 6cm2(for patient with ICRS grade 4)~  * patients with a major lesion of ICRS grade 3 which is larger than 6cm2(for patient without a ICRS grade 4),~3. Patient who had skin disease around target knee~4. patients who have a positive skin reaction to CS-10~5. Patients who had been administered with drugs such as oriental medicine, glucosamine and chondroitin within 14 days of baseline visit~6. Patients taking steroidal anti-inflammatory medications within 14 days of baseline visit~7. Patients with severe pain in other areas that could effect the diagnosis of the symptoms of the~8. History of surgery like arthroendoscopy within the past 6 months on the target knee~9. Patients who had been administered with immunosuppressants, including antirheumatic drugs (including methotrexate or antimetabolite), within the past 3 months~10. Patients who had been treated with physical therapy or herbal remedy (acupuncture, heat etc.) within 2 weeks of baseline visit~11. History of injection within the past 3 months on the target knee~12. Pregnant or breastfeeding female~13. With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, synovial chondromas)~14. With an infectious disease, including HIV or hepatitis~15. With any of the following clinically significant diseases:~    * heart disease (e.g., myocardial infarction, arrhythmia, other serious heart diseases, coronary artery bypass graft)~   * kidney disease (e.g., chronic renal failure, glomerulonephritis)~   * liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease)~   * endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease)~   * insulin-dependent diabetes mellitus~   * medical history of past or current malignant tumor~   * In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests:~      * Leukemia (White Blood Cell level in the hematology)~     * Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma (Alkaline phosphatase level in the hematology)~16. Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study~17. Patients who administered the TissueGene-C from past clinical trial~18. Considered inappropriate by the investigator for participation in this study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TissueGene-C (Type: EXPERIMENTAL): Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10\^7 cells
- Placebo (Type: PLACEBO_COMPARATOR): Single intra-articular injection to the damaged knee joint

Based on this trial design, predict the completion outcome and termination type (if applicable).